



FORUM EUROPÉEN, CŒUR, EXERCICE & PRÉVENTION



# RÉHABILITATION EN CARDIOLOGIE CONGÉNITALE

SOPHIE GUILLAUMONT

[s-guillaumont@chu-montpellier.fr](mailto:s-guillaumont@chu-montpellier.fr)

[guillaumont.s@institut-st-pierre.fr](mailto:guillaumont.s@institut-st-pierre.fr)



[www.forumeuropeen.com](http://www.forumeuropeen.com)



# Conflits d'intérêts

---

AUCUN

The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

Jane A. Leopold, M.D., *Editor*

## Cardiac Rehabilitation — Challenges, Advances, and the Road Ahead

Randal J. Thomas, M.D.

### Qualifying CVD Event or Diagnosis (inpatient or outpatient setting)

Identify patients who are eligible for CR  
Initiate secondary CVD prevention therapies  
Refer to outpatient CR program  
Assist with prompt CR enrollment



### CR Components

Attention to coexisting conditions  
Risk factor control  
Psychological support  
Nutrition therapy  
Physical activity  
Patient assessment and monitoring




### Long-Term Follow-up

Assess need for CVD risk reduction  
Provide updated treatment plan  
Encourage long-term maintenance  
Connect with long-term care provider

**Figure 1. Cardiac Rehabilitation (CR) Pathway.**

Important factors are listed for the three parts of the CR pathway, including steps to help patients initiate CR, components of an effective CR program, and steps to help patients maintain progress over time. CVD denotes cardiovascular disease.




## Physical activity interventions for people with congenital heart disease (Review)

Williams CA, Wadey C, Pieles G, Stuart G, Taylor RS, Long L

Cochrane Database Syst Rev. 2020

- 15 RCT (5 E , 10 A) : 924 patients
- 3 types d'intervention
- faible amélioration sur la capacité physique
- Évaluation au décours du programme
- réhabilitation plus que promotion
- peu significatif sur QLV
- pas de complications

Mean Difference  
IV, Random, 95% CI [mL/kg/min]




## Circulation

ORIGINAL RESEARCH ARTICLE




### **Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease**

- ACHD: 51% tabagisme, 30% obesité, 69% hypertension, 41%,hyperlipidemie, 7% diabetes
- Risque de syndrome coronarien aigu x 2.0 (95% CI, 1.5–2.8; P<0.001)
- Risque d'insuffisance cardiaque x 13.0 (95% CI, 9.4–18.1; P<0.001)



# ALERTES



## Atherosclerotic Cardiovascular Risk as an Emerging Priority in Pediatrics.

Schipper HS, de Ferranti S. *Pediatrics*. 2022


**Table 3. Risks of CVD by Type of Congenital HD**

	Coronary Artery Disease	Cerebrovascular Disease	Peripheral Vascular Disease
Repaired ASD/VSD	Not known to have increased risk	Increased risk if residual shunt	Not known to have increased risk
Bicuspid aortic valve	Potential risk after Ross procedure with reimplantation of coronary arteries	Not known to have increased risk	Increased risk related to aortic aneurysm
Coarctation of aorta	Increased risk could be related to accelerated atherosclerosis vs late hypertension	Increased risk related to residual hypertension or intracranial aneurysms	Increased risk related to residual coarctation or aortic aneurysm
Ebstein anomaly	Not known to have increased risk	Increased risk if interatrial shunt	Not known to have increased risk
Tetralogy of Fallot	Increased risk could be related to coronary anomalies	Increased risk if residual intracardiac shunt	Increased risk related to aortic dilation
TGA atrial switch	Increased risk could be related to coronary anomalies	Increased risk if residual baffle leak	Increased risk could be related to prior catheterizations
TGA arterial switch	Increased risk related to reduced coronary flow reserve, proximal intimal thickening, and coronary anomalies	Not known to have increased risk	Increased risk related to neo-aortic dilation
Fontan	Increased risk could be related to coronary anomalies	Increased risk if Fontan fenestration	Increased risk related to Fontan venous pressures and prior catheterizations
Cyanotic congenital HD	Potential decreased risk	Increased risk related to secondary erythrocytosis and hyperviscosity syndrome	Increased risk related to secondary erythrocytosis and hyperviscosity syndrome
Eisenmenger syndrome	Potential decreased risk	Increased risk related to secondary erythrocytosis and hyperviscosity syndrome	Increased risk related to secondary erythrocytosis and hyperviscosity syndrome

Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. de Ferranti SD & al. *Circulation*. 2019

# FACTEURS ASSOCIES A L' HYPO-ACTIVITE PHYSIQUE

- Altération de l'aptitude physique aérobie<sup>1</sup>
- Altération de la fonction musculaire<sup>2</sup>
- Manque d'autonomie, faible sentiment d'efficacité personnelle<sup>3</sup>
- Surprotection parentale<sup>4</sup>
- Principe de précaution appliqué par les médecins<sup>5</sup>



<sup>1</sup> Kempny et al. 2012, Amedro & al. 2017

<sup>2</sup> Kröönström et al. 2014



<sup>3</sup> Chen et al. Eur. 2015

<sup>4</sup> Reybrouck et al. 2005

<sup>5</sup> Swan et al. 2000



# FACTEURS LIMITANT ET MOTIVANT L'ACTIVITE PHYSIQUE




Bay et al. *Eur J Cardiovasc Nurs.* 2020, Pons C & al. 2021, Mora & al. 2019, Nazare & al. 2017, Majenemer & al. 2019

# The QUALIREHAB trial


## Main inclusion criteria

- 13-25 year old CHD patients
- $VO_{2max} < 80\%$  and /or VAT < 55%

12-month follow-up



142 adolescent and young adult CHD patients with impaired cardiopulmonary fitness randomly assigned to QUALIREHAB or standard of care



The QUALIREHAB program improved HRQoL (primary outcome), BMI, physical activity, and disease knowledge



European Heart Journal (2024) 00, 1–16  
 European Society of Cardiology <https://doi.org/10.1093/eurheartj/ehae085>

CLINICAL RESEARCH  
 Congenital heart disease

## Early hybrid cardiac rehabilitation in congenital heart disease: the QUALIREHAB trial

Pascal Amedro <sup>1,2\*</sup>, Arthur Gavotto <sup>3,4</sup>, Helena Huguet <sup>5</sup>, Luc Souilla <sup>6</sup>, Anne-Cecile Huby <sup>1,2</sup>, Stefan Matecki <sup>4</sup>, Anne Cadene <sup>5</sup>, Gregoire De La Villeon <sup>3,6</sup>, Marie Vincenti <sup>3,4,6</sup>, Oscar Werner <sup>3,6</sup>, Charlene Bredy <sup>3,7</sup>, Kathleen Lavastre <sup>3</sup>, Hamouda Abassi <sup>3,4</sup>, Sarah Cohen <sup>8</sup>, Sebastien Hascoet <sup>8</sup>, Claire Dauphin <sup>9</sup>, Aurelie Chalard <sup>9</sup>, Yves Dulac <sup>10</sup>, Nathalie Souletie <sup>10</sup>, Helene Bouvaist <sup>11</sup>, Stephanie Douchin <sup>11</sup>, Matthias Lachaud <sup>11</sup>, Caroline Ovaert <sup>12</sup>, Camille Soulatges <sup>12</sup>, Nicolas Combes <sup>13</sup>, Jean-Benoit Thambo <sup>1,2</sup>, Xavier Iriart <sup>1</sup>, Fanny Bajolle <sup>14</sup>, Damien Bonnet <sup>14</sup>, Helene Ansquer <sup>15</sup>, Jean-Guillaume Delpey <sup>15</sup>, Laurence Cohen <sup>16</sup>, Marie-Christine Picot <sup>5,17</sup>, and Sophie Guillaumont <sup>3,6</sup>; the QUALIREHAB Study Group

# QUALIREHAB : points déterminants

Rehabilitation centre



12-week  
rehabilitation  
program

Home



Critères de  
jugement

Intervention

Inclusion


Main inclusion criteria



- 13-25 year old CHD patients
- $VO_{2max} < 80\%$  and /or  $VAT < 55\%$



12-month  
follow-up




# QUALIREHAB: conception

M0 Inclusion

Randomisation


Intervention

M12 Critères de jugement



## RCT multicentrique

- 12 centres d'inclusion, 9 centres de réadaptation
- Promoteur CHU Montpellier, PHRIC,
- Investigateur coordinateur: Sophie Guillaumont
- Responsable scientifique: Pascal Amedro



# QUALIREHAB : inclusion et critères de jugement



## Main inclusion criteria



- 13-25 year old CHD patients
- $VO_{2max} < 80\%$  and /or  $VAT < 55\%$



12-month  
follow-up



# QUALIREHAB : intervention





Lessons from the TRANSITION-CHD randomized controlled trial







# QUALIREHAB : intervention



# QUALIREHAB : intervention






# QUALIREHAB essai randomisé contrôlé multicentrique

- **NSN :**

142 patients inclus  
(âge moyen 17,4 +/- 3,4)


- **CJP**

- Modification positive du score total du PEDS<sup>QL</sup> à 12 mois  
- Différence moyenne: 3.8  
(95%CI=[0.2;7.3]; P=0.038,  
effect size=0.34)




# QUALIREHAB essai randomisé contrôlé multicentrique

En ITT




# QUALIREHAB essai randomisé contrôlé multicentrique

En per protocole



# QUALIREHAB essai randomisé contrôlé multicentrique

- Résultats positifs sur la  $VO_{2max}$  à court terme
- Efficacité d'un programme hybride de 12 semaines



# QUALIREHAB essai randomisé contrôlé multicentrique

## Acceptabilité et Innocuité de l'intervention



Réalisation de plus de 80% des sessions pour 81% des patients




Taux de participation satisfaisant : 1ère semaine en centre (91%), séances à domicile (88%), and sessions de rappel en centre (77%).



Pas d'effet indésirable lié au programme de réhabilitation

# QUALIREHAB : perspectives et pistes d'amélioration



# QUALIREHAB : perspectives

Plateforme  
digitale


**Anamnèse**  
Anticiper . Accompagner . Accélérer



**Médana**  
Conçu par Anamnèse

Bienvenue


Connectez-vous pour  
accéder à votre  
application  
QualiNeuroRehab.




[www.forumeuropeen.com](http://www.forumeuropeen.com)



# QUALIREHAB : perspectives




*Johanna Calderon PhD*






# QUALIREHAB : perspectives







APA:

- Intensité
- Progression
- Personnalisation



# QUALIREHAB : perspectives



# QUALI-NEUROREHAB



## EXERCISE TRAINING

HIIT, cycle-ergometer + free physical activity (2 h per week, in presence and videoconference)



## NEURO-PSYCHOLOGICAL FEEDBACK

½ hour session per week with neuropsychologist



## DIGITAL PLATFORM

## PATIENT EDUCATION



Teleconsultation with nurse + digital content

## COGNITIVE TRAINING (COGMED)

½ hour individual session twice a week




[www.forumeuropeen.com](http://www.forumeuropeen.com)



Mathieu Andrianoely

Enseignant en APA / Doctorant

# Pathologies chroniques: QUALIREHAB-ONCO



Pediatric  
RESEARCH




## CLINICAL RESEARCH ARTICLE


Check for updates

### Impaired aerobic capacity in adolescents and young adults after treatment for cancer or non-malignant haematological disease

Arthur Gavotto<sup>1,2</sup>, Vincent Dubard<sup>1</sup>, Martina Avesani<sup>3</sup>, Helena Hugué<sup>4</sup>, Marie-Christine Picot<sup>4</sup>, Hamouda Abassi<sup>1</sup>, Sophie Guillaumont<sup>1,5</sup>, Gregoire De La Villeon<sup>1,5</sup>, Stephanie Haouy<sup>6</sup>, Nicolas Sirvent<sup>6</sup>, Anne Sirvent<sup>6</sup>, Alexandre Theron<sup>6</sup>, Anne Requirand<sup>1</sup>, Stefan Matecki<sup>1,2</sup> and Pascal Amedro<sup>3,7,8\*</sup>



# QUALIREHAB: parcours patient



\* By specialist physician, family doctor, nurse practitioner, etc.


\*\*Dietician, psychologist, neuropsychologist, psychiatrist, physiatrist, social worker, other subspecialists, etc.



# Doctors should be able to prescribe exercise like a drug

Few think that brief advice can change behaviour

Exercise is medicine: a call to action for physicians to assess and prescribe exercise



[www.forumeuropeen.com](http://www.forumeuropeen.com)

